Relay Therapeutics Inc [NASDAQ: RLAY] closed the trading session at $3.68 on 2025-07-24. The day’s price range saw the stock hit a low of $3.68, while the highest price level was $3.86.
The stocks have a year to date performance of -58.18 percent and weekly performance of 0.82 percent. The stock has been moved at -25.20 percent over the last six months. The stock has performed 11.18 percent around the most recent 30 days and changed 18.33 percent over the most recent 3-months.
If compared to the average trading volume of 1.94M shares, RLAY reached to a volume of 9801313 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Relay Therapeutics Inc [RLAY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RLAY shares is $14.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RLAY stock is a recommendation set at 1.45. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Relay Therapeutics Inc shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on April 17, 2025. While these analysts kept the previous recommendation, Jefferies raised their target price from $10.60 to $16. The new note on the price target was released on September 10, 2024, representing the official price target for Relay Therapeutics Inc stock. Previously, the target price had yet another raise to $20, while Goldman analysts kept a Buy rating on RLAY stock.
The Price to Book ratio for the last quarter was 0.87, with the Price to Cash per share for the same quarter was set at 4.14.
RLAY stock trade performance evaluation
Relay Therapeutics Inc [RLAY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.82. With this latest performance, RLAY shares gained by 11.18% in over the last four-week period, additionally sinking by -25.20% over the last 6 months – not to mention a drop of -10.68% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RLAY stock in for the last two-week period is set at 56.31, with the RSI for the last a single of trading hit 0.21, and the three-weeks RSI is set at 0.22 for Relay Therapeutics Inc [RLAY]. The present Moving Average for the last 50 days of trading for this stock 3.31, while it was recorded at 3.66 for the last single week of trading, and 4.05 for the last 200 days.
Relay Therapeutics Inc [RLAY]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Relay Therapeutics Inc [RLAY] shares currently have an operating margin of -4927.05% and a Gross Margin at 31.28%. Relay Therapeutics Inc’s Net Margin is presently recorded at -4341.53%.
Relay Therapeutics Inc (RLAY) Capital Structure & Debt Analysis
According to recent financial data for Relay Therapeutics Inc. ( RLAY), the Return on Equity (ROE) stands at -45.46%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -40.64%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Relay Therapeutics Inc’s Return on Invested Capital (ROIC) is -43.73%, showcasing its effectiveness in deploying capital for earnings.
Relay Therapeutics Inc (RLAY) Efficiency & Liquidity Metrics
Based on Relay Therapeutics Inc’s (RLAY) latest financial statements, the Debt-to-Equity Ratio is 0.07%, indicating its reliance on debt financing relative to shareholder equity.
Relay Therapeutics Inc (RLAY) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Relay Therapeutics Inc. (RLAY) effectively leverages its workforce, generating an average of -$1277356.32 per employee. The company’s liquidity position is robust, with a Current Ratio of 19.96% and a Quick Ratio of 19.96%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Relay Therapeutics Inc [RLAY] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RLAY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Relay Therapeutics Inc go to 10.39%.
Relay Therapeutics Inc [RLAY]: Institutional Ownership
There are presently around $105.68%, or 107.26% of RLAY stock, in the hands of institutional investors. The top three institutional holders of RLAY stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 27.9 million shares, which is approximately 21.0093%. VANGUARD GROUP INC, holding 11.7 million shares of the stock with an approximate value of $$76.32 million in RLAY stocks shares; and VANGUARD GROUP INC, currently with $$68.74 million in RLAY stock with ownership which is approximately 7.9375%.
